% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • insm_truth_teller insm_truth_teller May 19, 2013 8:30 AM Flag


    Once granted, the composition of matter patent provides exclusivity in any of the European Patent Office's member states where Insmed chooses to file at least through July 19, 2026.

    The U.S. Patent and Trademark Office issued a composition of matter patent covering the Company's liposomal amikacin for inhalation in August 2012, with U.S. exclusivity extending until at least August 2028.
    & Nebulizer device exclusivity for minimum of 15 years

11.83-0.05(-0.42%)May 27 4:00 PMEDT